PMID- 20002210
OWN - NLM
STAT- MEDLINE
DCOM- 20100513
LR  - 20240419
IS  - 1365-2567 (Electronic)
IS  - 0019-2805 (Print)
IS  - 0019-2805 (Linking)
VI  - 129
IP  - 4
DP  - 2010 Apr
TI  - Dendritic cells treated with resveratrol during differentiation from monocytes 
      gain substantial tolerogenic properties upon activation.
PG  - 525-35
LID - 10.1111/j.1365-2567.2009.03205.x [doi]
AB  - Resveratrol is a polyphenol that acts on multiple molecular targets important for 
      cell differentiation and activation. Dendritic cells (DCs) are a functionally 
      diverse cell type and represent the most potent antigen-presenting cells of the 
      immune system. In this study, we investigated resveratrol-induced effects on DCs 
      during their differentiation and maturation. Our results show that resveratrol 
      induces DC-associated tolerance, particularly when applied during DC 
      differentiation. Costimulatory molecules CD40, CD80 and CD86 were down-regulated, 
      as was the expression of major histocompatibility complex (MHC) class II 
      molecules. Surface expression of inhibitory immunoglobulin-like transcript 3 
      (ILT3) and ILT4 molecules was induced, while human leucocyte antigen (HLA)-G 
      expression was not affected. Resveratrol-treated DCs lost the ability to produce 
      interleukin (IL)-12p70 after activation, but had an increased ability to produce 
      IL-10. Such DCs were poor stimulators of allogeneic T cells and had lowered 
      ability to induce CD4(+) T-cell migration. Furthermore, treated cells were able 
      to generate allogeneic IL-10-secreting T cells, but were not competent in 
      inducing FoxP3 expression These tolerogenic effects are probably associated with 
      the effect of resveratrol on multiple molecular targets through which it 
      interferes with DC differentiation and nuclear factor (NF)-kappaB translocation. 
      Our data provide new insights into the molecular and functional mechanisms of the 
      tolerogenic effects that resveratrol exerts on DCs.
FAU - Svajger, Urban
AU  - Svajger U
AD  - Blood Transfusion Center of Slovenia, Slajmerjeva 6, Ljubljana, Slovenia. 
      svajgerurban@yahoo.com
FAU - Obermajer, Natasa
AU  - Obermajer N
FAU - Jeras, Matjaz
AU  - Jeras M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091125
PL  - England
TA  - Immunology
JT  - Immunology
JID - 0374672
RN  - 0 (Biomarkers)
RN  - 0 (LILRB2 protein, human)
RN  - 0 (LILRB4 protein, human)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Stilbenes)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Biomarkers/metabolism
MH  - CD4-Positive T-Lymphocytes/drug effects/immunology
MH  - *Cell Differentiation/drug effects/immunology
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/*drug effects/*immunology
MH  - Humans
MH  - Immune Tolerance/*drug effects/immunology
MH  - Interleukin-10/biosynthesis/immunology
MH  - Interleukin-12/biosynthesis/immunology
MH  - Lipopolysaccharides/pharmacology
MH  - Membrane Glycoproteins/antagonists & inhibitors/immunology
MH  - Monocytes/*cytology
MH  - NF-kappa B/immunology
MH  - Receptors, Cell Surface/antagonists & inhibitors/immunology
MH  - Receptors, Immunologic/antagonists & inhibitors/immunology
MH  - Reference Values
MH  - Resveratrol
MH  - Stilbenes/*pharmacology
PMC - PMC2842499
EDAT- 2009/12/17 06:00
MHDA- 2010/05/14 06:00
PMCR- 2011/04/01
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/05/14 06:00 [medline]
PHST- 2011/04/01 00:00 [pmc-release]
AID - IMM3205 [pii]
AID - 10.1111/j.1365-2567.2009.03205.x [doi]
PST - ppublish
SO  - Immunology. 2010 Apr;129(4):525-35. doi: 10.1111/j.1365-2567.2009.03205.x. Epub 
      2009 Nov 25.